Support for Cancer Clinical Trials Program

Up to $1.5M is available from the Support for Cancer Clinical Trials Program to support Multi-site Collaborative Cancer Clinical Trials Groups to develop industry-independent cancer clinical trial protocols.

Support for Cancer Clinical Trials Program

Support for Cancer Clinical Trials Program

Clinical trials benefit the community by improving the survival of people affected by cancer, and contribute to a reduction in premature death and disability. Clinical trials are fundamental to establishing if new cancer treatments, diagnostic tests or preventive interventions are effective and they help generate evidence for best-practice cancer care.

Under the Support for Cancer Clinical Trials program the Australian Government is supporting Australia’s cancer clinical trials capacity.

Through this program Cancer Australia supports 13 Multi-site Collaborative Cancer Clinical Trials Groups to develop industry-independent cancer clinical trial protocols.

 

Objectives

The primary aim of the Support for Cancer Clinical Trials program is to support Multi-site Collaborative Cancer Clinical Trials Groups to develop industry independent cancer clinical trial protocols.

The broader program objectives are to:

  • Increase the number of cancer clinical trials conducted in Australia
    • To increase the number of clinical trials opened from protocols developed by the Multi-site Collaborative Cancer Clinical Trials Groups or support the opening of larger trials which will increase the numbers of cancer patients recruited to clinical trials in Australia;
  • Increase the participation in clinical trials by people affected by cancer
    • To increase the participation of Australians in cancer clinical trials and encourage clinical trials representative of the sociodemographic distribution of specific cancer types in Australia;
  • Increase the number of clinical sites actively participating in cancer clinical trials
    • To increase the involvement in cancer clinical trials of public and private hospitals or centres, and sites in regional and remote areas of Australia;
  • Increase the involvement of policy makers, clinicians, researchers and consumers in the development of cancer clinical trials
    • To increase the involvement of key stakeholders in the development of cancer clinical trials that address the healthcare system’s most important clinical questions;
  • Increase National Cancer Cooperative Trials Group participation in national multi-group or international cancer clinical trials in Australia
    • To increase collaboration amongst Australian and international Collaborative Trials Groups in the development and conduct of cancer clinical trials

The outcome of this program is to guide scientific improvements in cancer prevention, treatment and care and in doing so build the evidence-base for best practice cancer care to improve health outcomes for Australian’s affected by
cancer.

 

Funding

The Australian Government, through its Agency Cancer Australia, is seeking funding applications from the 13 Multi-site Collaborative Cancer Clinical Trials Groups currently funded under the Support for Cancer Clinical Trials program. Cancer Australia will provide funding to each Multi-site Collaborative Cancer Clinical Trials Group of up to $500,000 GST-exclusive ($550,000 GST-inclusive) per financial year up to a maximum of $1,500,000 million GST-exclusive ($1,650,000 GST-inclusive) over a maximum three years. The funding will be provided to support the development of industry-independent cancer clinical trial protocols over a period of up to three years from 1 July 2018 – 30 June 2021. Cancer Australia will also provide access to National Technical Services to support the Multi-site Collaborative Cancer Clinical Trials Group: to develop industry-independent clinical trial protocols which include appropriate health economic and quality-of-life measures; to develop collaborative genomics based cancer clinical trial protocols; and provide access to training in cancer clinical trials design and development through ACORD.

 

Eligible Projects

The funding provided to each Multi-site Collaborative Cancer Clinical Trials Group under the Support for Cancer Clinical Trials program will be provided for direct costs associated with the development of industry-independent cancer clinical trial protocols.

It is expected that the funding awarded will be for staffing, administrative, and minor assets costs (up to $5,000 GST-exclusive) that support existing Multi-site Collaborative Cancer Clinical Trials Groups to develop industry-independent cancer clinical trial protocols to the stage of applying for grant funding and, in doing so, support the achievement of the program’s broader objectives.

 

Eligible Applicants

The following Multi-site Collaborative Cancer Clinical Trials Groups are eligible to apply for targeted competitive funding:

  • Australasian Gastro-Intestinal Trials Group;
  • Australasian Leukaemia and Lymphoma Group;
  • Australasian Lung Cancer Trials Group;
  • Australasian Sarcoma Study Group;
  • Australia and New Zealand Breast Cancer Trials Group;
  • Australia and New Zealand Melanoma Trials Group;
  • Australia New Zealand Gynaecological Oncology Group;
  • Australian and New Zealand Children’s Haematology and Oncology Group;
  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group;
  • Cooperative Trials Group for Neuro-Oncology;
  • Primary Care Collaborative Cancer Clinical Trials Group
  • Psycho-Oncology Co-operative Research Group; and
  • Trans-Tasman Radiation Oncology Group.

 

Timing

Applications close 30 May 2018.

 

More Information

2018-05-15T08:55:39+00:00May 15th, 2018|